News – Page 638 – Endpoints News

Galera shares take a nosedive in the wake of unexpected PhIII flop

4 years ago

Takeda, Wave Life Sciences revise their $230M R&D collaboration, dropping discovery work

4 years ago

Roche-Atea’s Covid-19 pill fails mid-stage trial, clouding future for closely watched program

4 years ago

Covid-19 roundup: FDA to give OK for mix-and-match booster shots — report; WHO group leads campaign to acquire ...

4 years ago

Sofinnova hauls in $548M to build and scale startups — as European VCs step up their biopharma game

4 years ago

Can an IDO/PD-L1 combo ever work? Novo-backed company spells out how in biotech's latest IPO filing

4 years ago

Still reeling from PhII failure, Calithera beefs up its oncology portfolio with a little help from Takeda

4 years ago

With hundreds of millions spent on failed accelerated approvals, researchers call for faster FDA withdrawals

4 years ago

Senate spending bill slashes funds for Biden's planned breakthrough drug accelerator at NIH

4 years ago

Crinetics spins out radiopharma efforts into a new company, highlighting the growing field's allure

4 years ago

FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease

4 years ago

Langer, Ciechanover godfather the latest AI upstart; Ipsen forges $446M AML development pact

4 years ago

Esperion gets out the budget ax, chopping 170 staffers as its big drug launch sputters

4 years ago

Omeros plunges deeper after FDA rejects rare disease drug, asking for more information

4 years ago

Third time's the charm: Adamis nabs approval of high-dose naloxone injection after two CRLs

4 years ago

Two drugmakers hit with PDUFA date delays from FDA amid backlog of inspections

4 years ago

Phathom's old Takeda drug bests Prevacid in a PhIII GI trial. Next stop? The FDA

4 years ago

Vertex gets much-needed win with ‘extraordinary’ first patient results on potential diabetes cure

4 years ago

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

4 years ago

FDA rejects Revance's pitch for Botox competitor as biotech blames manufacturing issues

4 years ago

Boehringer nabs FDA's first interchangeability designation for its Humira competitor — but will it matter?

4 years ago

Biogen hit by ALS setback with PhIII failure for tofersen — but follows a familiar strategy highlighting the ...

4 years ago

Covid-19 vaccine boosters earn big thumbs up, but Moderna draws ire over world supply; What's next for Merck’s ...

4 years ago

Roche's Tecentriq crosses the finish line first in adjuvant lung cancer, potentially kicking off gold rush

4 years ago

First page Previous page 635 636 637638639 640 641 Next page Last page